Syros Pharmaceuticals (SYRS) Appoints Deborah Dunsire to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors
September 10, 2021 7:30 AM EDTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Deborah Dunsire, M.D., to the Companys Board of Directors. Dr. Dunsire is a highly respected industry veteran with more than 30 years of clinical, commercial, and international management experience within the life sciences industry.
Deborah is a phenomenal leader with a track record of creating value through successful development and commercialization of life-changing new therapies for people with cancer and other serious diseases, said Nancy... More
